Cargando…
Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL
Phase I oncology clinical trials often comprise a limited number of patients representing different disease subtypes who are divided into cohorts receiving treatment(s) at different dosing levels and schedules. Here, we leverage a previously developed quantitative systems pharmacology model of the a...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339700/ https://www.ncbi.nlm.nih.gov/pubmed/36908269 http://dx.doi.org/10.1111/cts.13501 |